Comparison between Accretion Pharmaceuticals IPO and Sharvaya Metals IPO.
Accretion Pharmaceuticals IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Sharvaya Metals IPO is a SME Bookbuilding proposed to list at BSE SME.
| Accretion Pharmaceuticals IPO | Sharvaya Metals IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Jawa Capital Services Pvt.Ltd. | Expert Global Consultants Pvt.Ltd. |
| Registrar | Kfin Technologies Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Gretex Share Broking Pvt.Ltd. | Globalworth Securities Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Anchor Investor | Anchor Investor | Anchor Investor |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Accretion Pharmaceuticals IPO is up to ₹28.26 Cr whereas the issue size of the Sharvaya Metals IPO is up to ₹55.86 Cr. The final issue price of Accretion Pharmaceuticals IPO is ₹101.00 per share and of Sharvaya Metals IPO is ₹196.00 per share.
| Accretion Pharmaceuticals IPO | Sharvaya Metals IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹96.00 per share | ₹192.00 per share |
| Issue Price (Upper) | ₹101.00 per share | ₹196.00 per share |
| Issue Price (Final) | ₹101.00 per share | ₹196.00 per share |
| Discount (Retail) | ₹0.00 per share | |
| Discount (Employee) | ||
| Market Lot Size | 1200 shares | 600 shares |
| Fresh Issue Size | 27,98,400 shares | 23,50,000 shares |
| Fresh Issue Size (Amount) | up to ₹28.26 Cr | up to ₹46.06 Cr |
| OFS Issue Size | 0 shares | 5,00,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹9.80 Cr |
| Issue Size Total | 27,98,400 shares | 28,50,000 shares |
| Issue Size Total (Amount) | up to ₹28.26 Cr | up to ₹55.86 Cr |
Accretion Pharmaceuticals IPO opens on May 14, 2025, while Sharvaya Metals IPO opens on Sep 04, 2025. The closing date of Accretion Pharmaceuticals IPO and Sharvaya Metals IPO is May 16, 2025, and Sep 09, 2025, respectively.
| Accretion Pharmaceuticals IPO | Sharvaya Metals IPO | |
|---|---|---|
| Anchor Bid Date | May 13, 2025 | Sep 03, 2025 |
| Issue Open | May 14, 2025 | Sep 04, 2025 |
| Issue Close | May 16, 2025 | Sep 09, 2025 |
| Basis Of Allotment (Tentative) | May 19, 2025 | Sep 10, 2025 |
| Initiation of Refunds (Tentative) | May 20, 2025 | Sep 11, 2025 |
| Credit of Share (Tentative) | May 20, 2025 | Sep 11, 2025 |
| Listing date (Tentative) | May 21, 2025 | Sep 12, 2025 |
| Anchor Lockin End date 1 | Jun 18, 2025 | Oct 09, 2025 |
| Anchor Lockin End date 2 | Aug 17, 2025 | Dec 08, 2025 |
Accretion Pharmaceuticals IPO P/E ratio is 21.29, as compared to Sharvaya Metals IPO P/E ratio of .
| Accretion Pharmaceuticals IPO | Sharvaya Metals IPO | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Accretion Pharmaceuticals Limited Financial Information (Restated Consolidated)
| EBITDA | ||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100.00 | 88.29 | ||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 73.48 | 61.30 | ||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 21.29 | |||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹112.27 Cr. | |||||||||||||||||||||||||||||||||||||||||
| ROE | 72.47% | 54.92% | ||||||||||||||||||||||||||||||||||||||||
| ROCE | 36.73% | 49.39% | ||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.52 | 0.66 | ||||||||||||||||||||||||||||||||||||||||
| EPS | ₹4.74 | |||||||||||||||||||||||||||||||||||||||||
| RoNW | 72.47% | 54.92% | ||||||||||||||||||||||||||||||||||||||||
In the Accretion Pharmaceuticals IPO Retail Individual Investors (RII) are offered 12,22,800 shares while in Sharvaya Metals IPO retail investors are offered 12,22,800 shares. Qualified Institutional Buyers (QIB) are offered 1,41,600 shares in Accretion Pharmaceuticals IPO and 5,70,000 shares in Sharvaya Metals IPO.
| Accretion Pharmaceuticals IPO | Sharvaya Metals IPO | |
|---|---|---|
| Anchor Investor Reserveration | 2,11,200 shares | 8,53,200 shares |
| Market Maker Reserveration | 1,47,600 shares | 1,50,000 shares |
| QIB | 1,41,600 shares | 5,70,000 shares |
| NII | 12,22,800 shares | 4,28,400 shares |
| RII | 12,22,800 shares | 9,98,400 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 27,98,400 shares | 28,50,000 shares |
Accretion Pharmaceuticals IPO subscribed 7.67x in total, whereas Sharvaya Metals IPO subscribed 4.83x.
| Accretion Pharmaceuticals IPO | Sharvaya Metals IPO | |
|---|---|---|
| QIB (times) | 12.14x | 1.28x |
| NII (times) | 4.28x | 6.09x |
| Big NII (times) | 7.00x | |
| Small NII (times) | 4.31x | |
| RII (times) | 10.54x | 6.31x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 7.67x | 4.83x |
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
